Observational studyRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2026
Trends in antifungal use characteristics in primary care in Spain, 2019 to 2024: a nationwide study.
Observational study in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntifungal resistance is a growing global concern in the context of antimicrobial resistance. Although primary care is the main setting for managing superficial fungal infections, national evidence on antifungal consumption in Spain remains limited. This study analyzes the characteristics of antifungal use in Spanish primary care.
methodsA retrospective observational study was conducted using data from the Primary Care Clinical Database of the Spanish Ministry of Health. The study included individuals assigned to primary care with at least one antifungal dispensation per year between 2019-2024. Consumption was measured as Defined Daily Doses (DDD) per 1,000 inhabitants per day (DHD), following the WHO ATC/DDD methodology. Trends were analyzed by sex, age, municipality size, income level, country of birth, and employment status, using annual percentage change (APC) estimated through joinpoint regression models.
resultsFrom 2019 to 2024, antifungal DHD in Spanish primary care increased significantly overall (APC: 8.4% [6.2-10.5]; p<0.001 for both sexes); the number of individuals with ≥1 dispensation declined in 2020 and then stabilized (APC: 5.3% [2.0-8.6]; p=0.004). Use was consistently higher in women, especially among pensioners (with a widening gap after 2020), unemployed individuals, those with very low income, and those born in Spain; D01A led consumption. Significant APC values were observed across all age, country of birth, employment, municipality size, and income strata, with the largest increases in active workers, small and medium municipalities, males <15 years, and foreign-born.
conclusionsSystematic monitoring of antifungal consumption in primary care is key to anticipating shifts in epidemiology and guiding antifungal stewardship. This study provides the first nationwide assessment of outpatient antifungal use in Spain from 2019 to 2024, offering critical evidence for public health planning and antimicrobial resistance mitigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.